Undersøgelse af Cabozantinib hos deltagere med neuroendokrine tumorer, som allerede har modtaget tidligere behandling (CaboLife)
CaboLife: Et prospektivt ikke-interventionelt studie om effektivitet og sikkerhed af Cabozantinib i en virkelighedsnær kontekst for tidligere behandlede patienter med neuroendokrin tumor
This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).
These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.
The study will take place in regular hospitals and clinics in Germany and Austria.
It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life.
This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.
Studieoversigt
Status
Status
Betingelser
Betingelser
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Ipsen Clinical Study Enquiries
- Telefonnummer: See e mail
- E-mail: clinical.trials@ipsen.com
Studiesteder
-
-
-
Aschaffenburg, Tyskland
- Rekruttering
- MVZ am Klinikum Aschaffenburg
-
Berlin, Tyskland
- Rekruttering
- Evangelische Lungenklinik Berlin
-
Berlin, Tyskland
- Rekruttering
- DRK Kliniken Berlin
-
Berlin, Tyskland
- Rekruttering
- Charité - Universitaetsmedizin Berlin
-
Bonn, Tyskland
- Ikke rekrutterer endnu
- Johanniter-Kliniken Bonn
-
Bremen, Tyskland
- Rekruttering
- Krankenhaus St. Joseph-Stift Bremen GmbH
-
Chemnitz, Tyskland
- Ikke rekrutterer endnu
- Klinikum Chemnitz
-
Cologne, Tyskland
- Rekruttering
- pioh Studien und Mangement GbR
-
Cologne, Tyskland
- Rekruttering
- MVZ fuer Haematologie und Onkologie Koeln am Sachsenring
-
Dresden, Tyskland
- Rekruttering
- Gemeinschaftspraxis Haematologie - Onkologie
-
Dresden, Tyskland
- Rekruttering
- Technische Univiersitaet (TU) Dresden
-
Erlangen, Tyskland
- Rekruttering
- Universitaetsklinikum Erlangen
-
Essen, Tyskland
- Rekruttering
- Universitaetsklinikum Essen
-
Frankfurt, Tyskland
- Ikke rekrutterer endnu
- Krankenhaus Nordwest
-
Frankfurt am Main, Tyskland
- Ikke rekrutterer endnu
- Uniklinikum Frankfurt
-
Freiburg im Breisgau, Tyskland
- Rekruttering
- Universitaetsklinikum Freiburg
-
Giesen, Tyskland
- Ikke rekrutterer endnu
- Universitaetsklinikum Giessen-Marburg
-
Goettigen, Tyskland
- Rekruttering
- Universitaetsmedizin Goettingen
-
Hamburg, Tyskland
- Rekruttering
- Universitaetsklinikum Hamburg-Eppendorf
-
Hamburg, Tyskland
- Ikke rekrutterer endnu
- Asklepios Kliniken Hamburg
-
Heidelberg, Tyskland
- Ikke rekrutterer endnu
- Universitaetsklinikum Heidelberg
-
Kiel, Tyskland
- Ikke rekrutterer endnu
- UKSH Kiel
-
Leer, Tyskland
- Ikke rekrutterer endnu
- Studienzentrum UnterEms
-
Leipzig, Tyskland
- Ikke rekrutterer endnu
- MVZ Leipzig Mitte, MVZ Delitzsch
-
Leipzig, Tyskland
- Ikke rekrutterer endnu
- Universiteatsmedizin Leipzig
-
Ludwigsburg, Tyskland
- Rekruttering
- RKH Kliniken Ludwigsburg-Bietigheim gGmbH
-
Lübeck, Tyskland
- Ikke rekrutterer endnu
- UKSH Luebeck
-
Mainz, Tyskland
- Ikke rekrutterer endnu
- Universitaetsmedizin Mainz
-
Marburg, Tyskland
- Rekruttering
- Philipps-Universitaet Marburg
-
Minden, Tyskland
- Rekruttering
- Johannes Wesling Klinikum Minden der Muehlenkreiskliniken AoeR
-
Mülheim, Tyskland
- Rekruttering
- MVZ Muelheim an der Ruhr GmbH
-
München, Tyskland
- Ikke rekrutterer endnu
- TUM Klinikum Muenchen
-
Münster, Tyskland
- Ikke rekrutterer endnu
- Universitaetsklinikum Muenster
-
Osnabrück, Tyskland
- Ikke rekrutterer endnu
- MVZ Onkologie Klinikum Osnabrueck GmbH
-
Saarbrücken, Tyskland
- Ikke rekrutterer endnu
- Universitaestklinikum Saarbruecken
-
Tübingen, Tyskland
- Rekruttering
- Universitätsklinikum Tuebingen
-
Westerstede, Tyskland
- Rekruttering
- Medizinische Studiengesellschaft Nord-West
-
Würzburg, Tyskland
- Rekruttering
- Universitaetsklinikum Wuerzburg
-
-
-
-
-
Graz, Østrig
- Rekruttering
- Medizinische Universitaet Graz
-
Linz, Østrig
- Ikke rekrutterer endnu
- Kepler Universitaetsklinikum GmbH Linz
-
Vienna, Østrig
- Rekruttering
- Medizinische Universität Wien
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
150 adult participants in Austria and Germany who are prescribed cabozantinib tablets for unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues prior to entry into the study will be included.
Beskrivelse
Inclusion Criteria:
Participants can join the study if they meet all of the following conditions:
- Are 18 years or older and able to give informed consent.
- Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study.
- Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
- Have already received at least one prior systemic therapy, other than somatostatin analogues.
- Have signed a written informed consent form.
Exclusion Criteria:
Participants cannot join the study if:
- They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study.
- They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Disease Control Rate (DCR)
Tidsramme: At 6 Months
|
Proportion of participants who achieve complete response, partial response, or stable disease within 6 months of cabozantinib treatment, based on radiographic assessments performed as part of routine care. |
At 6 Months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (ORR)
Tidsramme: Up to 18 Months
|
Proportion of participants who achieve complete or partial response based on radiographic assessments. |
Up to 18 Months
|
|
Change from baseline in global and subscale scores of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)
Tidsramme: Baseline and Every 3 Months up to 18 Months
|
A validated 30-item questionnaire designed to assess the general health-related quality of life of cancer patients. It includes: 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) a global health status/QoL scale and several single items (e.g., dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). |
Baseline and Every 3 Months up to 18 Months
|
|
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors Module (EORTC QLQ-GINET21)
Tidsramme: Baseline and Every 3 Months up to 18 Months
|
A 21-item module developed to supplement the QLQ-C30 for patients with gastrointestinal neuroendocrine tumors (GI-NETs). It includes 5 scales (Endocrine symptoms, Gastrointestinal symptoms, Treatment-related side effects, Social functioning, Disease-related worries) and 5 single items (weight loss, weight gain, muscle and/or bone pain, information, sexual functioning). |
Baseline and Every 3 Months up to 18 Months
|
|
Percentage of participants experiencing Adverse Events (AEs), non-serious, drug-related, or serious Adverse Events (SAEs)
Tidsramme: Up to 18 Months
|
An Adverse event (AE) is any untoward medical occurrence, temporally associated with the use of study intervention, whether or not related to the study intervention. |
Up to 18 Months
|
|
Percentage of participants with any dose modification due to AEs.
Tidsramme: Up to 18 months
|
Percentage of participants who experienced at least one dose reduction, interruption, or discontinuation due to adverse events during the study period. |
Up to 18 months
|
|
Duration of treatment (DoT)
Tidsramme: Up to 18 Months
|
Time from first dose to last dose of cabozantinib. |
Up to 18 Months
|
|
Percentage of participants switching to a new line of therapy
Tidsramme: Up to 18 Months
|
Percentage of participants who initiated a new line of therapy during the study period. The type of therapy received after switch will be reported descriptively and is not considered a formal outcome measure. |
Up to 18 Months
|
|
Disease control rate after switch to next line of therapy
Tidsramme: 3 Months After Therapy Switch
|
Proportion of participants achieving complete response, partial response, or stable disease within 3 months after switching to a new therapy, based on radiographic assessment performed as part of routine care. |
3 Months After Therapy Switch
|
|
Chromogranin A Levels
Tidsramme: Baseline and Every 3 Months up to 18 Months
|
Chromogranin A blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Neuron-Specific Enolase blood levels.
Tidsramme: Baseline and Every 3 Months up to 18 Months
|
Neuron-Specific Enolase blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Time to next treatment
Tidsramme: Up to 18 Months
|
Time from first dose of cabozantinib to initiation of subsequent therapy. |
Up to 18 Months
|
|
Progression-Free Survival (PFS)
Tidsramme: Up to 18 Months
|
Time from first dose of cabozantinib to disease progression or death from any cause. |
Up to 18 Months
|
|
Progression-Free Survival Rate at 12 and 18 Months
Tidsramme: At 12 and 18 Months
|
Number of participants without disease progression or death. |
At 12 and 18 Months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Ipsen Medical Director, Ipsen
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CLIN-60000-467
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD-delingstidsramme
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the United States (US) and/or Europe (EU).
IPD-delingsadgangskriterier
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .